Swartz has been a fixture at Voyager since 2021, building a resume that spans nearly every facet of the business. Her tenure includes leadership roles in clinical development, finance, and legal affairs, alongside her most recent responsibilities as chief business officer and chief operating officer. This broad operational experience positions her to oversee the company’s internal strategy as it moves through a critical phase of research.
In section Market Quotes
Robin Swartz Named Incoming CEO of Voyager Therapeutics
Robin Swartz will lead Voyager Therapeutics as the biotechnology firm prepares for a multi-year executive transition. Currently serving as president, she is slated to step into the chief executive officer role in early 2027, succeeding incumbent Alfred Sandrock as the company advances its clinical pipeline for Alzheimer’s disease.
Alfred Sandrock will retain the top post until the company gathers early safety data from its clinical trial of VY1706. This investigational gene therapy for early-stage Alzheimer’s remains the primary focus of the firm's current development efforts. Once the data milestone is reached and the leadership handover is finalized, Sandrock plans to transition to a seat on the company’s board of directors to provide ongoing strategic guidance.
Comments (0)
No comments yet. Be the first!